Spyre Therapeutics shares are trading higher after the company reported a year-over-year increase in Q4 EPS results. Also, Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $35.
Portfolio Pulse from Benzinga Newsdesk
Spyre Therapeutics shares surged following a report of increased Q4 EPS year-over-year. Additionally, Wells Fargo upgraded SYRE from Equal-Weight to Overweight and increased its price target from $12 to $35.
March 01, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spyre Therapeutics reported a year-over-year increase in Q4 EPS, and Wells Fargo upgraded the stock from Equal-Weight to Overweight, raising the price target from $12 to $35.
The positive earnings report indicates strong financial health and operational success, which typically leads to increased investor confidence and stock demand. The upgrade and significant price target raise by Wells Fargo further validate the company's growth prospects, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100